MedTrace Logo

Pediatric Prospective Personalized Immune and Target Identification Trial

NCT04859543 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-05-01

No results posted yet for this study

Summary

PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular profiling to define the best matching targeted and immune treatment for relapsed, refractory or very high risk pediatric CNS tumors.

Conditions

  • Central Nervous System Neoplasms
  • Pediatric Cancer
  • GEN1 Gene Mutation
  • Tumor, Brain

Interventions

DEVICE

FoundationOneHeme

Tumor tissue obtained during standard surgery will be subsequently examined histopathologically and the content of cancer cells will be determined. Broad molecular profiling of the tumor; with potential results finding such molecular changes, for which the specific targeted anti-tumor treatment will be performed.

Sponsors & Collaborators

  • Brno University Hospital

    collaborator OTHER

  • Roche s.r.o.

    collaborator UNKNOWN

  • Masaryk University

    lead OTHER

Principal Investigators

  • Jaroslav Sterba, Prof, MD · Brno University Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-02
Primary Completion
2024-12-10
Completion
2024-12-10

Countries

  • Austria
  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04859543 on ClinicalTrials.gov